




Supplementary material



Supplementary Figure S1. Correlation between duplicate assays (presented as arbitrary ELISA units) of all cohort samples (n=1462).




Supplementary Figure S2. Cumulative incidence of graft loss adjusted for competing death for the four groups (Nabs-/DSA-, Nabs-/DSA+, Nabs+/DSA- and Nabs+/DSA+).



Supplementary Figure S3. Graft survival according to different definitions of Nabs+.

Kaplan-Meier curves depicting the graft survival of Nabs+ and Nabs- kidney transplant recipients with Nabs+ defined as (A) > 25% increase in reactivity to MDA between sera collected post-transplant and pre-transplant, (B) > 75 % increase, (C) > 100% increase and (D) > 200% increase.



Supplementary Figure S4. Graft survival as a function of Nabs and sex or donor type.

Kaplan-Meier curves depicting graft survival according to (A) Nabs status and recipient's sex, (B) Nabs status and living or deceased donor type, and (C) Nabs status and extended criteria donor (ECD) or standard criteria donor (SCD) status.

Supplementary Table S1. Intraassay and interassay variation of MDA ELISA

Assay	Intraassay mean (ELISA units)^a	Intraassay SD	Intraassay CV (%)
1 (week 1)	50.87	1.38	2.70
2 (week 3)	47.28	1.76	3.72
3 (week 5)	47.67	1.85	3.89
4 (week 7)	45.76	1.55	3.39
5 (week 9)	49.97	2.86	5.73
6 (week 11)	50.56	2.18	4.32
Interassay mean	48.69		
Interassay SD	2.07		
Interassay CV (%)	4.26		

^amean of 5-10 wells of representative sample per assay
CV, coefficient of variation; SD, standard deviation